Podophyllum Granules 4x 4 X Tablet is a Health Canada–registered human drug (DIN 00767697) held by Homeocan Inc., containing Podophyllum. Health Canada lists its status as Cancelled Post Market (status date 14 Oct 1997). Nexara Health has matched 12 registrations of Podophyllum across 1 other regulated market, 1 of them in the same strength and dosage form.
Health Canada registration
| DIN | 00767697 |
|---|---|
| Brand name | Podophyllum Granules 4x |
| Active ingredient | Podophyllum |
| Strength | 4 X |
| Dosage form | Tablet |
| Route | Oral |
| Company | Homeocan Inc. |
| Status | Cancelled Post Market — 14 Oct 1997 |
| Class | Human |
| ATC | |
| AHFS | 92:02.00* ; See footnote |
| Regulator record | Health Canada DPD entry · Product monograph |
Podophyllum registered in other markets
12 registrations of the same molecule in 1 national registry outside Canada (first 8 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| United States | Bestmade Natural Products Podophyllum | Bestmade Natural Products | Tablet, Soluble | listed | FDA NDC | |
| United States | BM Podophyllum | BM Private Limited | Globule | listed | FDA NDC | |
| United States | Podophyllum Pelt Kit Refill | Washington Homeopathic Products | Pellet | listed | FDA NDC | |
| United States | Podophyllum peltatum | Boiron | Pellet | listed | FDA NDC | |
| United States | Podophyllum peltatum | Boiron | Pellet | listed | FDA NDC | |
| United States | Podophyllum peltatum | Boiron | Pellet | listed | FDA NDC | |
| United States | Podophyllum peltatum | Boiron | Pellet | listed | FDA NDC | |
| United States | Podophyllum peltatum | Boiron | Pellet | listed | FDA NDC |
See every manufacturer of Podophyllum worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Podophyllum Granules 4x (DIN 00767697) marketed in Canada?
No. Health Canada lists DIN 00767697 as Cancelled Post Market as of 14 Oct 1997.
Who holds the Canadian licence for this product?
Homeocan Inc. is the company of record in the Health Canada Drug Product Database.
Is Podophyllum registered outside Canada?
Yes — Nexara Health has matched 12 registrations in 1 other market, including 1 in the same strength and dosage form (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 00767697, status date 1997-10-14; national medicine registries: FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 00767697, status date 1997-10-14; national medicine registries: FDA NDC.
Health Canada Drug Product Database (DPD), DIN 00767697, status date 1997-10-14; national medicine registries: FDA NDC. Last reviewed 2026-09-17. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.